TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07607015: Instara™-1 Dual Perspectives on Continuous Glucose Monitoring: Understanding Patient Experience and Healthcare Professional Preferences

Sponsor: Getz Pharma · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 75 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT07607015 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07607015 Rescue Dossier →